“…Fold change in MIC results from parent isolate to terminal mutant [Figure: see text] METHODS: Serial passaging was performed in broth microdilution (BMD) for CAZ-AVI, IMI-REL, C/T, meropenem (MEM), cefepime (FEP), and piperacillin-tazobactam (P/T). …”
Enlace del recurso
Enlace del recurso

“…We evaluated the in vitro activity of these 5 BL/BLIs and comparators against P. aeruginosa (PSA) causing cystic fibrosis (CF) pulmonary exacerbation. [Figure: see text] [Figure: see text] METHODS: 383 PSA isolates (1/patient) were recovered from 35 medical centers in the US (n=187) and 12 European countries (EU; n=196) in 2018-2021 and susceptibility tested by CLSI broth microdilution method. …”
Enlace del recurso
Enlace del recurso

“…The activity of PLZ (99.3% susceptible [S]) was comparable to that of colistin and higher than other comparators against ESBL isolates (Figure). AMK inhibited 96.4% of the isolates and GEN and TOB inhibited 57.9% and 43.5%, respectively. …”
Enlace del recurso
Enlace del recurso

“…RESULTS: Plazomicin (MIC(50/90) ranges, 0.25–0.5/1–2 µg/mL) inhibited 98.8–99.9% of the ENT isolates at ≤4 µg/mL across all infection types (figure). At ≤4 µg/mL, plazomicin inhibited 93.8–100% of the carbapenem-resistant ENT (CRE) isolates stratified by infection type. …”
Enlace del recurso
Enlace del recurso

“…RESULTS: All BLs had limited activity against CRE isolates (MIC(50/90), ≥32/ >32 mg/L) and QPX lowered the MIC for all agents (figure). Against 157 isolates carrying serine-carbapenemase (SCarb) genes (153 KPC-producers), MEM or ETP plus QPX at fixed 4 or 8 mg/L displayed MIC(50) at ≤ 0.03 mg/L and MIC(90) ranging from 0.12 to 0.5 mg/L. …”
Enlace del recurso
Enlace del recurso

“…In this study, the in vitro susceptibilities of DLX and comparator quinolones were determined for clinical isolates from US CF patients collected during 2019-2021. [Figure: see text] METHODS: Isolates from CF patients hospitalized with pneumonia were consecutively collected at 17 US medical centers participating in the SENTRY Surveillance Program. …”
Enlace del recurso
Enlace del recurso

“…We evaluated the in vitro activity of manogepix and comparators against 2,810 geographically diverse fungal isolates collected in the SENTRY Surveillance Program during 2020-2021 and stratified them by infection type. [Figure: see text] METHODS: Antifungal susceptibility testing of manogepix and comparator agents was conducted according to CLSI M27 (2017) and M38 (2017) guidelines. …”
Enlace del recurso
Enlace del recurso

“…Susceptibilities of SM and ACB to MIN and comparators, 2014-2021 [Figure: see text] METHODS: Isolates were collected from hospitalized patients in 35 US medical centers. …”
Enlace del recurso
Enlace del recurso

“…We evaluated the activity of ceftazidime-avibactam (CAZ-AVI) and aztreonam-avibactam (ATM-AVI) and comparators against common BLs detected in US hospitals. [Figure: see text] METHODS: A total of 21,853 Enterobacterales (ENT) isolates collected during 2020–2021 were susceptibility (S) tested by reference broth microdilution methods. …”
Enlace del recurso
Enlace del recurso

“…This study compared VITEK2 to the broth microdilution method (BMD) when reporting S results against a challenge set of NF-GNB isolates. [Figure: see text] METHODS: A challenge set of PSA (62 isolates; 21 carbapenem-resistant [CR] and 20 cefepime [CEP]-R), ACB (64; 21-CR and 21 CEP-R), and SM (33; 11 trimethoprim-sulfamethoxazole [TS]-R) were collected (1/patient) in 2019–2021 from 43 medical centers located in 9 US Census Divisions and identified by MALDI-TOF MS. …”
Enlace del recurso
Enlace del recurso

“…As aminoglycosides are frequently used to treat infections caused by multidrug-resistant (MDR) and carbapenem-resistant Enterobacterales (CRE), we evaluated the activity of plazomicin and the impact of CLSI breakpoint changes on the susceptibility rates of Enterobacterales collected from US medical centers. [Figure: see text] METHODS: 5,725 Enterobacterales isolates were consecutively collected (1/patient) from 36 US medical centers in 2020–2022 and susceptibility tested by broth microdilution against amikacin, gentamicin, tobramycin, and plazomicin. …”
Enlace del recurso
Enlace del recurso

“…In this study, the in vitro susceptibilities of DLX and comparator fluoroquinolones (FQ), levofloxacin (LEV), moxifloxacin (MOX), and ciprofloxacin (CIP) were determined for US clinical isolates. [Figure: see text] METHODS: Isolates from SSSI were consecutively collected at 77 US medical centers participating in the SENTRY Surveillance Program (2017–2022). …”
Enlace del recurso
Enlace del recurso

“…Activity of sulbactam-durlobactam (fixed 4 mg/L), antibacterial combinations, and comparators against a set of 66 A. baumannii-calcoaceticus species complex isolates [Figure: see text] METHODS: Bacterial isolates consisted of 41 ACB isolates from the Centers for Disease Control and Prevention Antimicrobial Resistance Bank and 25 molecularly characterized cefiderocol-resistant ACB clinical isolates from the SENTRY Antimicrobial Surveillance Program. …”
Enlace del recurso
Enlace del recurso

“…This study determined the in vitro activity of OMC and comparators against bacterial clinical isolates collected from patients with bone/joint infections (BJI) from the OMC surveillance program (2015–2022). [Figure: see text] METHODS: 876 bacterial isolates from bone/joint infections were received from 39 medical centers in the USA and 16 European countries (2015–2022). …”
Enlace del recurso
Enlace del recurso

“…This study evaluated the activity of BPR and comparator agents against E. faecalis isolated from patients hospitalized in US medical centers. [Figure: see text] METHODS: A total of 1,834 E. faecalis isolated from 34 US medical centers (2016–2020) were included. …”
Enlace del recurso
Enlace del recurso

“…We evaluated the in vitro activity of RZF, caspofungin (CSF), micafungin (MCF), anidulafungin (ANF), and azoles against a global collection of 500 Candida isolates causing IC. [Figure: see text] METHODS: C. albicans (CA; 233 isolates; 46.6%), C. glabrata (CG; 102; 20.4%), C. parapsilosis (CP; 82; 16.4%), C. tropicalis (CT; 41; 8.2%), C. krusei (CK; 18; 3.6%), C. dubliniensis (CD; 15; 3.0%), and C. auris (CARS; 9; 1.8%) isolates were collected (1/patient) in 2022 from 52 medical centers located in Europe (EU; n=203; 19 centers), North America (NA; n=167; 14 centers), Asia-Pacific (AP; n=63; 8 centers), and Latin America (LA, n=67; 7 centers), identified by MALDI-TOF MS and/or sequencing and tested by CLSI broth microdilution. …”
Enlace del recurso
Enlace del recurso

“…The activity of OMC and comparators was evaluated against S. pneumoniae (SPN) from the USA, as well as the resistance (R) mechanisms in tetracycline (TET) non-susceptible (NS) SPN. [Figure: see text] METHODS: 1,038 SPN from 31 USA centers (2019-2021) were tested by CLSI broth microdilution. …”
Enlace del recurso
Enlace del recurso

“…Rezafungin (RZF), a new ECH approved by the US FDA to treat candidemia and invasive candidiasis, was evaluated against a collection of ECH–non-wild type (NWT) CGLA isolates. [Figure: see text] METHODS: A total of 1045 CGLA collected (1/patient) in 2014–2021 from 58 medical centers located in North America (NA; n=459; 20 centers), Europe (EU; n=396; 23 centers), Asia-Pacific (AP; n=130; 10 centers), and Latin America (LA, n=60; 5 centers) were identified by MALDI-TOF and/or sequencing and tested by CLSI broth microdilution. …”
Enlace del recurso
Enlace del recurso

“…We evaluated the frequency and antimicrobial susceptibility of Gram-negative bacteria (GNB) causing pneumonia in US hospitals. [Figure: see text] METHODS: Bacterial isolates were consecutively collected (1/patient) from patients hospitalized with pneumonia and the susceptibility of GNBs (3,911 Enterobacterales [ENT] and 2,753 non-fermenters) was evaluated by broth microdilution. …”
Enlace del recurso
Enlace del recurso

“…This methodology can be expanded to other species. Figure 1 [Image: see text] DISCLOSURES: Rodrigo E. …”
Enlace del recurso
Enlace del recurso